Skip to main content
Erschienen in: International Journal of Clinical Pharmacy 5/2015

01.10.2015 | Research Article

Non-prescription treatment of NSAID induced GORD by Australian pharmacies: a national simulated patient study

verfasst von: Brett MacFarlane, Andrew Matthews, Jenny Bergin

Erschienen in: International Journal of Clinical Pharmacy | Ausgabe 5/2015

Einloggen, um Zugang zu erhalten

Abstract

Background Patients regularly present to community pharmacies for advice about and treatment for reflux symptoms and NSAIDs are a common cause of these symptoms. There is no published literature detailing the approach that pharmacies take to these enquiries, the pharmacotherapy they recommend or whether they contribute to the safe and effective use of reflux medicines. Objectives To assess in an observational study design the clinical history gathering, recommendations for GORD management and counselling provided by community pharmacies in a simulated patient scenario involving suspected NSAID induced reflux symptoms. Setting Australian community pharmacies. Method Simulated patients visited 223 community pharmacies to request treatment for reflux symptoms. The interaction was audiotaped and assessed against guidelines for the treatment of reflux symptoms. Main outcome measures Alignment of community pharmacies with international expert gastroenterologist guidance and national professional practice guidelines for the treatment of reflux symptoms by pharmacists including: consultation with a pharmacist; confirmation of reflux diagnosis based on symptoms; recommendation of short courses proton pump inhibitor (PPI) therapy; advice on the safe and effective use of reflux medicines and referral to a doctor for further assessment. Results Pharmacists consulted with the simulated patient in 77 % of cases. Symptoms were enquired about in 95 % of cases and a medicines history taken in 69 % of cases. Recommendations for treatment included: PPIs (18 %), histamine H2 antagonists (57 %) and antacids (19 %). Advice on product use was given in 83 % of cases. Referral to a doctor to discuss reflux symptoms was made in 63 % of cases. Conclusion When assessing patients for the symptoms of GORD, Australian pharmacists and non-pharmacist support staff take a comprehensive history including symptomatology, duration of symptoms, concomitant medicines and medical conditions and any GORD treatments previously trialled. They provide comprehensive counselling on the use of antisecretory and antacid medicines. Counselling could involve more comprehensive information on lifestyle approaches for GORD management and side effects of antisecretory and antacid medicines. Further alignment with guidelines for the management of GORD would result in greater referral to a doctor for assessment of recurrent GORD and greater recommendation of PPIs for symptoms. However alignment with guidelines by all pharmacists is unrealistic if the guidelines are not universally available to them.
Literatur
1.
Zurück zum Zitat Loffeld RJ. Gastro-oesophageal reflux disease-experience in daily practice: symptoms and symptom assessment. Scand J Gastroenterol Suppl. 2006;243:3–6.CrossRefPubMed Loffeld RJ. Gastro-oesophageal reflux disease-experience in daily practice: symptoms and symptom assessment. Scand J Gastroenterol Suppl. 2006;243:3–6.CrossRefPubMed
2.
Zurück zum Zitat Ronkainen J, Aro P, Storskrubb T, et al. High prevalence of gastroesophageal reflux symptoms and esophagitis with or without symptoms in the general adult Swedish population: a Kalixanda study report. Scand J Gastroenterol. 2005;40(3):275–85.CrossRefPubMed Ronkainen J, Aro P, Storskrubb T, et al. High prevalence of gastroesophageal reflux symptoms and esophagitis with or without symptoms in the general adult Swedish population: a Kalixanda study report. Scand J Gastroenterol. 2005;40(3):275–85.CrossRefPubMed
3.
Zurück zum Zitat Zagari RM, Fuccio L, Wallander MA, et al. Gastro-oesophageal reflux symptoms, oesophagitis and Barrett’s oesophagus in the general population: the Loiano–Monghidoro study. Gut. 2008;57(10):1354–9.CrossRefPubMed Zagari RM, Fuccio L, Wallander MA, et al. Gastro-oesophageal reflux symptoms, oesophagitis and Barrett’s oesophagus in the general population: the Loiano–Monghidoro study. Gut. 2008;57(10):1354–9.CrossRefPubMed
4.
Zurück zum Zitat Liker HR, Ducrotté P, Malfertheiner P. Unmet medical needs among patients with gastroesophageal reflux disease: a foundation for improving management in primary care. Dig Dis. 2009;27(1):62–7.CrossRefPubMed Liker HR, Ducrotté P, Malfertheiner P. Unmet medical needs among patients with gastroesophageal reflux disease: a foundation for improving management in primary care. Dig Dis. 2009;27(1):62–7.CrossRefPubMed
5.
Zurück zum Zitat Ruszniewski P, Soufflet C, Barthélémy P. Nonsteroidal anti-inflammatory drug use as a risk factor for gastro-oesophageal reflux disease: an observational study. Aliment Pharmacol Ther. 2008;28(9):1134–9.CrossRefPubMed Ruszniewski P, Soufflet C, Barthélémy P. Nonsteroidal anti-inflammatory drug use as a risk factor for gastro-oesophageal reflux disease: an observational study. Aliment Pharmacol Ther. 2008;28(9):1134–9.CrossRefPubMed
6.
Zurück zum Zitat Martín-De-Argila C, Martínez-Jiménez P. Epidemiological study on the incidence of gastroesophageal reflux disease symptoms in patients in acute treatment with NSAIDs. Expert Rev Gastroenterol Hepatol. 2013;7(1):27–33.CrossRefPubMed Martín-De-Argila C, Martínez-Jiménez P. Epidemiological study on the incidence of gastroesophageal reflux disease symptoms in patients in acute treatment with NSAIDs. Expert Rev Gastroenterol Hepatol. 2013;7(1):27–33.CrossRefPubMed
7.
Zurück zum Zitat Sigterman KE, van Pinxteren B, Bonis PA, Lau J, Numans ME. Short-term treatment with proton pump inhibitors, H2-receptor antagonists and prokinetics for gastro-oesophageal reflux disease-like symptoms and endoscopy negative reflux disease. Cochrane Database Syst Rev. 2013;5:CD002095. doi:10.1002/14651858.CD002095.pub5.PubMed Sigterman KE, van Pinxteren B, Bonis PA, Lau J, Numans ME. Short-term treatment with proton pump inhibitors, H2-receptor antagonists and prokinetics for gastro-oesophageal reflux disease-like symptoms and endoscopy negative reflux disease. Cochrane Database Syst Rev. 2013;5:CD002095. doi:10.​1002/​14651858.​CD002095.​pub5.PubMed
8.
Zurück zum Zitat Zhang JX, Ji MY, Song J, Lei HB, Qiu S, Wang J, et al. Proton pump inhibitor for non-erosive reflux disease: a meta-analysis. World J Gastroenterol. 2013;19(45):8408–19.PubMedCentralCrossRefPubMed Zhang JX, Ji MY, Song J, Lei HB, Qiu S, Wang J, et al. Proton pump inhibitor for non-erosive reflux disease: a meta-analysis. World J Gastroenterol. 2013;19(45):8408–19.PubMedCentralCrossRefPubMed
9.
Zurück zum Zitat Holtmann G, Bigard MA, Malfertheiner P, Pounder R. Guidance of the use of over the counter proton pump inhibitors for the treatment of GORD. Int J Clin Pharm. 2011;33(3):493–500.CrossRefPubMed Holtmann G, Bigard MA, Malfertheiner P, Pounder R. Guidance of the use of over the counter proton pump inhibitors for the treatment of GORD. Int J Clin Pharm. 2011;33(3):493–500.CrossRefPubMed
10.
Zurück zum Zitat Bundeff AW, Zaiken K. Impact of clinical pharmacists’ recommendations on a proton pump inhibitor taper protocol in an ambulatory care practice. J Manag Care Pharm. 2013;19(4):325–33.PubMed Bundeff AW, Zaiken K. Impact of clinical pharmacists’ recommendations on a proton pump inhibitor taper protocol in an ambulatory care practice. J Manag Care Pharm. 2013;19(4):325–33.PubMed
11.
Zurück zum Zitat Atkins R, Smith L. Impact of pharmacy intervention on the use of proton pump inhibitors in the hospital setting. Consult Pharm. 2013;28(12):786–92.CrossRefPubMed Atkins R, Smith L. Impact of pharmacy intervention on the use of proton pump inhibitors in the hospital setting. Consult Pharm. 2013;28(12):786–92.CrossRefPubMed
12.
Zurück zum Zitat Branham AR, Katz AJ, Moose JL, et al. Retrospective analysis of estimated cost avoidance following pharmacist provided medication therapy management services. J Pharm Pract. 2013;26(4):420–7.CrossRefPubMed Branham AR, Katz AJ, Moose JL, et al. Retrospective analysis of estimated cost avoidance following pharmacist provided medication therapy management services. J Pharm Pract. 2013;26(4):420–7.CrossRefPubMed
13.
Zurück zum Zitat Benrimoj SI, Werner JB, Raffaele C, Roberts AS. A system for monitoring quality standards in the provision of non-prescription medicines from Australian community pharmacies. Pharm World Sci. 2008;30:147–53.CrossRefPubMed Benrimoj SI, Werner JB, Raffaele C, Roberts AS. A system for monitoring quality standards in the provision of non-prescription medicines from Australian community pharmacies. Pharm World Sci. 2008;30:147–53.CrossRefPubMed
15.
Zurück zum Zitat Kashyap KC, Nissen LM, Smith SS, Kyle G. Management of over the counter insomnia complaints in Australian community pharmacies: a standardised patient study. Int J Pharm Pract. 2014;22:125–34.CrossRefPubMed Kashyap KC, Nissen LM, Smith SS, Kyle G. Management of over the counter insomnia complaints in Australian community pharmacies: a standardised patient study. Int J Pharm Pract. 2014;22:125–34.CrossRefPubMed
16.
Zurück zum Zitat Queddeng K, Chaar B, Williams K. Emergency contraception in Australian community pharmacies: a simulated patient study. Contraception. 2011;83(2):176–82.CrossRefPubMed Queddeng K, Chaar B, Williams K. Emergency contraception in Australian community pharmacies: a simulated patient study. Contraception. 2011;83(2):176–82.CrossRefPubMed
17.
Zurück zum Zitat Schneider CR, Emery L, Brostek R, Clifford RM. Evaluation of the supply of antifungal medication for the treatment of vaginal thrush in the community pharmacy setting: a randomized controlled trial. Pharm Pract (Granada). 2013;11(3):132–7.CrossRef Schneider CR, Emery L, Brostek R, Clifford RM. Evaluation of the supply of antifungal medication for the treatment of vaginal thrush in the community pharmacy setting: a randomized controlled trial. Pharm Pract (Granada). 2013;11(3):132–7.CrossRef
18.
Zurück zum Zitat Schneider CR, Gudka S, Fleischer L, Clifford RM. The use of a written assessment checklist for the provision of emergency contraception via community pharmacies: a simulated patient study. Pharm Pract (Granada). 2013;11(3):127–31.CrossRef Schneider CR, Gudka S, Fleischer L, Clifford RM. The use of a written assessment checklist for the provision of emergency contraception via community pharmacies: a simulated patient study. Pharm Pract (Granada). 2013;11(3):127–31.CrossRef
Metadaten
Titel
Non-prescription treatment of NSAID induced GORD by Australian pharmacies: a national simulated patient study
verfasst von
Brett MacFarlane
Andrew Matthews
Jenny Bergin
Publikationsdatum
01.10.2015
Verlag
Springer Netherlands
Erschienen in
International Journal of Clinical Pharmacy / Ausgabe 5/2015
Print ISSN: 2210-7703
Elektronische ISSN: 2210-7711
DOI
https://doi.org/10.1007/s11096-015-0129-9

Weitere Artikel der Ausgabe 5/2015

International Journal of Clinical Pharmacy 5/2015 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.